Image
Loading

prime DX® Liquid - Molecular tumour profile in liquid biopsy

The new prime DX® Liquid test consists of a panel of 1021 genes, which analyses the immunotherapy biomarkers TMB, MSI, HLA, allowing the treating physician to plan an effective treatment for the patient, including immunotherapy, chemotherapy, PARP inhibitors and compatibility of participation in clinical trials.

In addition,

prime DX® Liquid, analyses genes involved in genetic predisposition to cancer, thus providing information to the physician about the likelihood of an inherited cancer syndrome.

Recommended for the following cases:
  • When there is not enough tissue or recent biopsy
  • If the tissue quality is poor (e.g. too much bone in the sample)
  • When there is a metastatic and multifocal disease
  • After treatment to check patient’s response
  • If the patient relapses and there is a need for molecular profiling without biopsy

Liquid Biopsy - Advantages

Tissue biopsy is the test of choice for testing the molecular profile of the tumor. On the hand, Liquid biopsy is an alternative method in which free circulating genetic material (ctDNA) from the tumour in a blood sample is isolated and tested. All in all, liquid biopsy tests have several advantages, which are:
  • Non-invasive method (blood sampling)

  • Possibility of successive analyses – monitoring the progress of the disease

  • Low failure rate (~3%) due to unsuitability of the material

  • Better assessment of the genetic heterogeneity of the tumour

RESULTS REPORT

The results of the prime DX® Liquid analysis include a detailed explanation of all findings, including the following information.
  • Molecular profiling of the tumor tissue with details on specific gene mutations and interactive access to information related to the specific gene

  • Suggested approved therapies that can be of great benefit to the specific patient with interactive access to clinical studies.

  • Suggested approved therapies that can be of great benefit to the specific patient with interactive access to clinical studies.

  • Recommended treatments under investigation with interactive access to clinical trials.

  • Treatments with associated resistance that will not be of benefit to the specific patient.

  • Medication suggestions with documented indications.

Technical characteristics of the prime DX® Liquid test

The new prime DX® test is based on advanced molecular technology using hybridization capture NGS with UMIs. The test uses the Oncology Multi-Gene Variant Assay (GenePlus), which is a qualitative in vitro diagnostic test (CE-IVD) that detects variants in 1021 tumour-related genes and gene rearrangements/mergers in 38 genes, in a liquid biopsy.

Also, it analyzes biomarkers for response to immunotherapy, including HLA detection and biomarkers for response to chemotherapy.

The MGI-DNBSEQ-G400 is a CE-IVD platform that enables simultaneous processing of multiple samples with high sensitivity and specificity, producing faster, reliable results at a lower cost

Image

Frequently Asked Questions Physicians

Which patients are eligible for the test?

All patients with a solid tumour when there is insufficient tissue or recent biopsy are suitable.

How long does it take to get my results?

 

15 business days

 

What kind of sample and how much is required for the test?

 

The prime DX Liquid analysis is performed on a liquid biopsy and we need blood in special vials that you will receive from Genekor. (Cell-Free DNA BCT®(10ml) και Cell-Free RNA BCT®(10ml)).

Why is it necessary to analyse so many genes?

  • Quantity and quality of information
  • Reduced time
  • Reduced costs

A multi-gene panel results in the production of a large volume of multi-level valuable information, greatly increasing the likelihood of finding a personalized treatment plan for the patient.

Also, it has been shown that the more genes analysed, the more reliable the results for TMB.

Are there any special transportation conditions?

The blood sample (liquid biopsy) should be transported in conditions up to 20°C.

Image

Frequently Asked Questions Patients

Why should I sign the consent form?

 

For the use of the patient’s genetic material for testing, ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012 require the written consent of each patient.

Does any public/private insurance cover the test?

For information about the cost coverage of the test you should contact your insurance company.

How can I pay for the test?

 

Payment can be made by bank transfer or debit/credit card.

How can I send my sample?

 

To schedule pickup and return of your sample, please contact us.

How will I receive my results?

 

Your results are shared with your GP via email.

How to order the test?

Our Customer Service Team is committed to answering your questions about the services offered by Genekor. If you are interested in any of the tests offered by Genekor, please contact us directly.

 

*To complete the test, you are required to complete and send the Consent form that you will find on the link below.

If you want to send us your sample, please contact us to arrange all procedures.
CONTACT

*For more information on scientific content please contact: scientific.support@genekor.com

*Download the promotional brochure here.